Advancing Theranostics in Oncology: Radiopharmaceuticals from Discovery to Clinical Applications
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 30 June 2026 | Viewed by 31
Special Issue Editors
Interests: positron emission tomography; somatostatin receptor imaging; targeted radionuclide therapy; Alpha particle; Auger electron
Special Issues, Collections and Topics in MDPI journals
Interests: positron emission tomography; radiopharmaceutical therapy; drug discovery; theranostics; oncology
Special Issues, Collections and Topics in MDPI journals
2. Sherbrooke Molecular Imaging Center (CIMS), Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke (CRCHUS), 3001, 12e Avenue Nord, Sherbrooke, QC J1H 5N4, Canada
3. Institut de Recherche sur le Cancer de l’Université de Sherbrooke (IRCUS), Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
Interests: positron pmission tomography; diagnostic imaging; radiopharmaceuticals; radiochemistry; personalized medicine
Special Issue Information
Dear Colleagues,
An unprecedented number of radiopharmaceuticals are entering clinical settings for the diagnosis and treatment of cancers. This progress in theranostics is driven by advances in drug development, radioisotope production, synthetic chemistry, instrumentation, and image quantification. Several PET imaging agents targeting the estrogen receptor and prostate-specific membrane antigen have been approved for clinical use in the past few years, and clinical investigation is underway regarding other promising targets such as the fibroblast-activating protein. From a therapeutic perspective, there has been rapid growth in and adoption of beta emitters for treating neuroendocrine tumors and prostate cancer, and multiple novel radiopharmaceuticals utilizing alpha emitters are emerging. Given the significant interest from both academia and industry, we anticipate that this accelerating trend of radiopharmaceutical development will continue. This Special Issue will highlight recent developments in diagnostic and therapeutic radiopharmaceuticals for cancers from bench to bedside. Original research papers and review articles are welcome for this Special Issue.
Dr. Hwan Lee
Dr. Joseph Lau
Dr. Etienne Rousseau
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- theranostics
- radiopharmaceutical
- positron emission tomography
- single photon emission computed tomography
- targeted radionuclide therapy
- dosimetry
- cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
